

Innovus Pharma


CORPORATE PROFILE

Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

9171 Towne Centre Drive, Ste 440 IR@InnovusPharma.com
San Diego, CA 92122 T: (858) 964-5123
Phone: (858) 964-5123
Fax: (858) 249-7879
<http://www.innovuspharma.com>
info@innovuspharma.com

STOCK PERFORMANCE

Symbol	INNV
Exchange	OTCQB
Market Cap.	22.3m
52 Week Range	0.08 - 0.21
Close	0.1075
Volume	222
Shares Outstanding	216,469,857
As of Nov 16, 2018 3:56 pm	



MANAGEMENT TEAM

Bassam Damaj, Ph.D. - President and Chief Executive Officer

Randy Berholtz, MBA/JD - Executive Vice President, Corporate Development and General Counsel

Rauly Gutierrez, CPA - Vice President, Finance and Principal Financial and Accounting Officer

RECENT HEADLINES

[Nov 14, 2018 - Innovus Pharma Reports Another New Quarterly Revenue Record of Approximately \\$7.4 Million for the Third Quarter 2018 and \\$19.2 Million for the First Nine Months of 2018](#)

[Nov 8, 2018 - Innovus Pharmaceuticals to Release Its Third Quarter 2018 Financial Results on Wednesday, November 14, 2018](#)

[Nov 5, 2018 - Innovus Pharmaceuticals Reports Preliminary Q3 2018 Sales Revenue of \\$7.0 million to \\$7.1 million](#)

[Oct 25, 2018 - SeeThruEquity Issues Update on Innovus Pharmaceuticals and Raises Target Price to \\$0.80](#)

[Oct 23, 2018 - Innovus Pharma Receives Approval for Medicare Reimbursement for its GlucoGorx\(TM\) Blood Glucose Monitoring System and GlucoGorx\(TM\) Blood Glucose Test Strip Products](#)

PAST EVENTS

Apr 30, 2016 - The San Diego Union Tribune Successful Aging Expo